MIF and non-small cell lung carcinoma: Importantly, the functional overlap of MIF and D-DT in NSCLC pro-tumorigenic pathways provides strong rationale for the simultaneous therapeutic targeting of MIF and D-DT in lung adenocarcinoma malignant disease.